Denmark's weight-loss drug market is seeing a slow-burning competition between domestic giant Novo Nordisk and US rival Eli Lilly. While Eli Lilly set out to challenge Novo on its home turf last spring, its patient numbers significantly lag after a year. Approximately 4,000 Danes use Eli Lilly's Mounjaro, compared to 110,000 using Novo Nordisk's Wegovy.
A Marathon, Not a Sprint
Patrik Jonsson, a senior executive at Eli Lilly, acknowledged the slower-than-expected entry into the Danish market. He stated the company is prepared for a longer timeline. 'In Denmark, it takes longer, but we have the time, and we are going to fix it,' Jonsson said. He expressed confidence in the progress but admitted it is taking longer than anticipated. Jonsson believes patient experiences and healthcare system feedback will ultimately determine the market leaders. He pointed to other European countries like Finland, Sweden, Germany, and Italy where this pattern has played out. 'We increase our share every week and every month on new patients starting treatment,' he noted, adding that healthcare staff report Mounjaro as more effective and preferred by some patients who have tried both.
A Doctor's Warning on Rapid Expansion
The competition is viewed with concern by some medical professionals. Maria KrĂĽger, a practicing doctor and chair of the Danish Society for General Medicine, warns against an overly aggressive market expansion. 'I think one must be careful about expanding the market so violently, because you risk overtreating and pathologizing too many people,' KrĂĽger said. She provided an example from her own practice, meeting many post-menopausal women determined to lose weight. She observes that many lose muscle mass in their arms, legs, and buttocks, which she does not consider healthy. This raises concerns about the broader implications of widespread medication use for weight loss.
The Core Challenge of Market Access
When questioned about the modest figure of fewer than 4,000 patients in a year, Jonsson framed Eli Lilly's strategy as a long-term endeavor. 'It is not a sprint. It is a marathon,' he explained. He identified market access as the primary hurdle. 'Very few patients have access, so our first priority is to ensure that patients in need of medical treatment for obesity should have access to it,' Jonsson stated. This highlights a fundamental business and healthcare challenge: penetrating a system where a well-established domestic competitor already has deep roots and a significant patient base.
The Domestic Giant's Home Advantage
Novo Nordisk's Wegovy, with 110,000 Danish users, clearly holds a formidable home-field advantage. The disparity in patient numbers—27 times more users for the Danish product—illustrates the scale of the challenge facing Eli Lilly. This advantage is built on existing relationships with the Danish healthcare system, prescriber familiarity, and likely an integrated position within treatment guidelines. For Danish physicians, initiating treatment with a well-known entity like Novo Nordisk often presents a lower perceived barrier than opting for a newer, foreign alternative.
Looking at the European Landscape
Jonsson's reference to other European markets suggests Eli Lilly's strategy is based on a proven playbook. The company has observed that initial slow uptake can be followed by significant market share gains as real-world evidence from patients and doctors accumulates. The argument that Mounjaro is perceived as more effective by some healthcare professionals is a key part of their long-term value proposition. However, replicating this success in Denmark, the home country of its main rival, presents a unique set of logistical and reputational challenges that may not exist elsewhere.
Patient Choice in a Growing Market
The central thesis from Eli Lilly is that patient choice and clinical experience will drive change over time. The company is betting that as more Danish patients try Mounjaro, their positive experiences will gradually shift prescription patterns. This is a patient-centric argument that positions the competition as beneficial for consumer choice and outcomes. However, this process requires patients to be prescribed the drug in the first place, which circles back to the initial access problem that Jonsson identified as the key bottleneck.
The Broader Health Policy Question
Maria Krüger's concerns shift the focus from market competition to public health policy. Her warning about overtreatment and the medicalization of weight, especially with potential side effects like muscle loss, introduces a critical perspective. It questions whether the business-driven 'kapløb' or race between pharmaceutical companies aligns perfectly with optimal, balanced patient care. This tension between commercial interests and healthcare ethics forms an undercurrent to the entire story, relevant for Danish policymakers and medical boards overseeing treatment guidelines.
What Comes Next in Denmark?
The next year will be crucial for Eli Lilly's Danish ambitions. The company has stated its commitment to fixing the access issues, but concrete steps remain unspecified. Will it involve different pricing models, more intensive educational outreach to doctors, or lobbying for changes in prescription protocols? Meanwhile, Novo Nordisk will work to maintain its dominant position and likely continue its own innovations. For Danish patients, this slow-burning rivalry could eventually mean more options, but the medical community urges that the focus must remain on appropriate and necessary treatment, not just market share.